Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Nusinersen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,877,944Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA & EMA Accept Higher Dose Nusinersen Applications In SMA
    FDA & EMA Accept Higher Dose Nusinersen Applications In SMA

    23 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/23/3014181/0/en/FDA-and-EMA-Accept-Applications-for-Higher-Dose-Regimen-of-Nusinersen-in-SMA.html

    GLOBENEWSWIRE
    23 Jan 2025
    Share Share
    Biogen reports promising results for higher dose of Spinraza
    Biogen reports promising results for higher dose of Spinraza

    10 Oct 2024

    // PRESS RELEASE

    https://investors.biogen.com/news-releases/news-release-details/new-higher-dose-nusinersen-efficacy-and-safety-data-presented

    PRESS RELEASE
    10 Oct 2024
    Share Share
    Biogen Reports Positive Results For Higher Dose Nusinersen
    Biogen Reports Positive Results For Higher Dose Nusinersen

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940411/0/en/Biogen-Announces-Positive-Topline-Results-from-Study-of-Higher-Dose-Regimen-of-Nusinersen-Showing-Significant-Benefit-in-Treatment-of-SMA.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Russia registers domestic generic of Spinraza
    Russia registers domestic generic of Spinraza

    14 May 2024

    // THE PHARMA LETTER

    https://www.thepharmaletter.com/article/russia-registers-domestic-generic-of-spinraza

    THE PHARMA LETTER
    14 May 2024
    Share Share
    Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA
    Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA

    06 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/06/2841312/0/en/New-Biomarker-Data-Add-Further-Evidence-Supporting-the-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-after-Gene-Therapy.html

    GLOBENEWSWIRE
    06 Mar 2024
    Share Share
    New Data at Cure SMA Highlight Potential Benefit of SPINRAZA
    New Data at Cure SMA Highlight Potential Benefit of SPINRAZA

    30 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/30/2698081/0/en/New-Data-at-Cure-SMA-Highlight-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-After-Gene-Therapy.html

    GLOBENEWSWIRE
    30 Jun 2023
    Share Share